Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 29, 2024 08:00 ET | Source: Alumis Inc.

Alumis Initiates ONWARD Phase 3 Clinical Program Evaluating ESK-001, an Oral TYK2 Inhibitor, in Moderate-to-Severe Plaque Psoriasis

Alumis announced that patient dosing has commenced in the ONWARD Phase 3 clinical program for ESK-001 for the treatment of psoriasis.
June 27, 2024 23:57 ET | Source: Alumis Inc.

Alumis Announces Pricing of Initial Public Offering

Alumis, a clinical-stage biopharmaceutical company developing oral therapies for immune mediated diseases, announces pricing of initial public offering